Cerebrovascular Disease
22nd Princeton Conference

This 2002 text surveys the current status and future directions of stroke pathophysiology, diagnosis and treatment.

Pak H. Chan (Edited by)

9780521187534, Cambridge University Press

Paperback, published 17 February 2011

488 pages
24.4 x 17 x 2.5 cm, 0.77 kg

"Anyone with a basic understanding of stroke, who wants or needs to be brought reasonably up to date (the conference was held three years ago) should read this book. The subject matter is topical, and exciting breakthroughs are explained. ...this book fills an important gap." Journal of Neurosurgery, May 2003

Prevention, diagnosis and treatment are the watchwords in stroke research, for basic neuroscientists and clinicians alike. This 2002 book, from the 22nd Princeton Conference on Cerebrovascular Disease, contains contributions from outstanding investigators on numerous topics in stroke research. The contents cover the status and future directions of stroke pathophysiology, diagnosis and treatment, with special emphasis on the molecular and cellular mechanisms of ischaemic cell death and repair, and clinical issues including imaging, risk factors and therapeutic strategies in stroke. Available in both print and online formats, this survey of the basic and clinical science of stroke is an essential resource for all involved in advancing knowledge of cerebrovascular disease.

Part I: 1. Zinc toxicity in the ischemic brain
1. 2. Central nervous system ischemia: diversity among the caspases
Part II: 3. Peroxynirite and injury to the vasculature and central nervous system in stroke and neurodegeneration
4. Interaction between inducible nitric oxide and cyclooxygenase-2 in ischemic brain injury
5. Mechanisms of ischemic tolerance
6. Clinically-tolerated NMDA receptor antagonists and newly cloned NMDA receptor subunits that mimic them
Part III: 7. Cell death programs in neutral development and disease
8. Apoptotic gene expression in brain Ischemia and ischemic tolerance
9. Cellular mechanisms of white matter ischemia: what can we learn from culture models?
Part IV: 10. Astrocytes in ischemic stroke
11. Aquaporin-4 water channels and brain edema
12. Neuroprotection with tetracyclines in brain ischemia models
13. Spreading depression: a teleologic means for self-protection from brain ischemia
Part V: 14. The role of matrix metalloproteinases and urokinase in blood-brain barrier damage with thrombolysis
15. Does brain nitric oxide generation influence tissue oxygenation after severe human subarachnoid hemorrhage?
16. Tissue plasminogen activator and hemorrhagic brain injury
17. Dynamics of infarct evolution after permanent and transient focal brain ischemia in mice
Part VI: 18. Inflammation and stroke: benefits or harm?
19. TNF-a and ceramide are involved in the mediation of neuronal tolerance to brain ischemia
20. Sites and mechanisms of IL-1 action in ischemic and excitotoxic brain damage
21. Protease generation, inflammation and cerebral microvascular activation
Part VII: 22. Adenoviral vectors for gene therapy in stroke
23. Gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury
24. Vasomotor effects of nitric oxide, superoxide dismutases and calcitonin gene-related peptide
Part VIII: 25. Transplantation of neural stem cells: cellular and gene therapy in pediatric hypoxic-ischemic brain injury
26. Neural plasticity after cerebral ischemia
27. Environmental effects on recovery after stroke
Part IX: 28. Magnetic resonance imaging in stroke trials
29. Disappearing deficits and disappearing lesions: diffusion/perfusion MRI in TIA and intra-arterial thrombolysis
30. Diffusion and perfusion magnetic resonance imaging in the evaluation of acute ischemic stroke
31. Early recanalization in acute ischemic stroke saves tissue at risk defined by stroke magnetic resonance imaging
Part X: 32. Vascular factors in Alzheimer's disease
33. Beyond neuroprotection: the protection of axons and oligodendrocytes in cerebral ischemia
34. Combining neuroprotection with thrombolysis: how to translate laboratory success to our clinical trials
35. Prospects for improved neuroprotection trials in stroke
36. Basic research and stroke therapeutics: what have we learned?

Subject Areas: Neurology & clinical neurophysiology [MJN]